Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase for acute AQP4-IgG-positive neuromyelitis optica spectrum disorder
2024-517176-38-00Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Aug 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Erasmus MC. Primary endpoint: Depletion of circulating pathogenic anti-AQP4 IgG. Started Aug 2025; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2024-517176-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517176-38-00.